NCResNet: Noncoding Ribonucleic Acid Prediction Based on a Deep Resident Network of Ribonucleic Acid Sequences.

NCResNet: Noncoding Ribonucleic Acid Prediction Based on a Deep Resident Network of Ribonucleic Acid Sequences.

Noncoding RNA (ncRNA) is a type of RNA that plays a vital role in many biological processes, diseases, and cancer, while not able to be translated into proteins. With the development of the next generation sequence technology, thousands of novel RNA with long open reading frames (ORFs, the length of the longest ORF> 303 nt) and the short ORFs (the longest ORF length ≤ 303 nt) have been found in a short time. How to identify ncRNAs rather than unannotated Novel RNA is an important step for the functional analysis of RNA, regulatory RNA, etc. However, most previous methods only utilize the information of the sequence features.

Meanwhile, most of them have focused on long-ORF sequences RNA, but are not adapted to the short-ORF sequences of RNA. In this paper, we propose a new reliable method called NCResNet. NCResNet employs 57 features a hybrid of four categories of inputs, including sequence, protein, structural RNA, and RNA physicochemical properties, and introduce additional features and feature an in-depth policy learning neural network model to adapt to this issue. Experiments on the benchmark dataset of 8 species show NCResNet have higher accuracy and higher Matthews correlation coefficient (MCC) as compared with the state-of-the-art other methods.

Especially, in four short ORF RNA sequence datasets, especially mouse, Saccharomyces cerevisiae, zebrafish, and cattle, NCResNet Achieves greater than 10 and a 15% improvement over state-of-the-art methods in terms of accuracy and MCC. Meanwhile, the long-ORF RNA sequence dataset, NCResNet also have better accuracy and MCC of state-of-the-art other methods in most test dataset. Code and data are available

NCResNet: Noncoding Ribonucleic Acid Prediction Based on a Deep Resident Network of Ribonucleic Acid Sequences.
NCResNet: Noncoding Ribonucleic Acid Prediction Based on a Deep Resident Network of Ribonucleic Acid Sequences.

A Comprehensive Analysis Identifying differentially expressed Circular Key Ribonucleic Acid and Methylation-Related Functions in pheochromocytomas and Paragangliomas.

We investigated differentially expressed RNAs circular (circRNAs) and their potential function in pheochromocytomas and paragangliomas (PCC / PGLs). circRNAs level of expression in tumor and adjacent normal tissue from seven patients PCC / PGL analyzed through RNA sequencing. Real-time PCR was performed to verify the main candidates identified in the sequencing data. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway analysis (KEGG) is performed to predict the function of this circRNAs.

A total of 367 circRNAs found differentially expressed between tumor and normal samples. Three related histone methylation-circRNAs (hsa_circ_0000567, hsa_circ_0002897, and hsa_circ_0004473) and target their microRNAs (miRNA) have been identified and validated. We then mapped circRNA-miRNA-messenger RNA (mRNA) coding-noncoding gene co-expression (CNC) network to demonstrate the potential of binding relationship between circRNAs and target them at the PCC / PGLs.

Five mRNAs, miRNAs 88, and 132 associated with the pathogenesis circRNAs be used to map the network CNC, and we observed that the candidate’s interaction with their target miRNAs regulated histone methylation and subsequently mediated PCC / PGL pathogenesis. This study is the first to provide the entire profile of circRNAs were expressed differently in the PCC / PGLs. Our data indicate that the modified circRNAs can control the pathogenesis of PCC / PGLs to regulate histone methylation process, highlighting their role as potential biomarkers.

Goat IgG (-ve control for flow cytometry) (isotype control)

20011-100 100 test
EUR 123.6

BSA Control for Age-BSA

2221-BSA each
EUR 210

BSA Control for AGE-BSA

35R-AA007 10 mg
EUR 268.8
Description: BSA Control for AGE protein (BSA modified), Cat No. 30R-AA007

Flow Control Fitting for Flypad

FLY1254 EACH
EUR 101.84

Control for ER, 4 cases (1.5mm)

ERC081 1
EUR 102
Description: IHC control array containing 4 breast cancer cases of strong, moderate, weak/nil estrogen receptor (ER) expressers in duplicates

Control for PR, 3 cases (1.5mm)

PRC061 1
EUR 102
Description: IHC control array containing 3 breast cancer cases of strong, moderate, low/negative progesterone receptor (PR) expressers in duplicates

Flow Control Fitting for Blowgun

FLY1252 EACH
EUR 80.95

Deer IgG, semi-pure for ELISA (Control, non-immune, isotype control)

20024-2 100 ug
EUR 270

Control for DOG1, 3 cases (1.5mm)

DOG1061 1
EUR 102
Description: IHC control array containing 3 GIST cases of strong, moderate, weak/nil DOG1 expressers in duplicates

Control for HER2, 4 cases (1.5mm)

HRC081 1
EUR 102
Description: IHC control array containing 4 breast cancer cases of strong, moderate, low and negative HER2 breast cancer expressers in duplicates

Control for Ckit, 6 samples (1.5mm)

CKIT061 1
EUR 102
Description: Gastrointestinal stroma tumors, 6 cores, 3 cases in duplicates showing strong, moderate and no expression of cKit molecule.

Control/Blocking peptide for Human WNT-1

WNT111-P 100 ug
EUR 548.4

SLLK, Control Peptide for TSP1 Inhibitor

HY-P0301 1mg
EUR 159.6

Control/Blocking peptide for Human WNT5a

WNT511-P 100 ug
EUR 196.8

Rec. Human CD21 protein control for WB

CD21-C 100 ul
EUR 343.2

PAS/Glycogen, For Digestion (Control Slides)

TCS0024-100 100 Slides
EUR 847.2

PAS/Glycogen, For Digestion (Control Slides)

TCS0024-25 25 Slides
EUR 278.4

PAS/Glycogen, For Digestion (Control Slides)

TCS0024-5 5 Slides
EUR 117.6

Thiostatin Rat protein, control for western

TSTN11-C 100 ul
EUR 343.2

Mouse IgG (-ve control for flow cytometry)

20008-1-100 100 tests
EUR 123.6

Rabbit IgG (-ve control for flow cytometry)

20009-1-100 100 tests
EUR 123.6

NATtrol Respiratory Panel 2 (RP2) Controls (Ea)

NATRPC2-BIO Ea
EUR 550.46
Description: Please contact Gentaur in order to receive the datasheet of the product.

Recombinant (E. coli, >95%) purified human p53 (wild type) protein control for WB

P5311-C 100 ul
EUR 343.2

Control Sections for FD NeuroSilver™ Kit

PCS101 each
EUR 69.6

Purified, Human S100 protein control for WB

S1002-C 100 ul
EUR 343.2

Negative Control Antibody for Mouse Monoclonals

V8785-100UG 100ug
EUR 349.3
Description: To serve as a true negative control for various procedures, this monoclonal IgG should be used under the identical conditions and at the same dilution as the rabbit monoclonal antibody being used for a positive reaction.

Negative Control Antibody for Mouse Monoclonals

V8785-20UG 20ug
EUR 153.3
Description: To serve as a true negative control for various procedures, this monoclonal IgG should be used under the identical conditions and at the same dilution as the rabbit monoclonal antibody being used for a positive reaction.

Negative Control Antibody for Mouse Monoclonals

V8785SAF-100UG 100ug
EUR 349.3
Description: To serve as a true negative control for various procedures, this monoclonal IgG should be used under the identical conditions and at the same dilution as the rabbit monoclonal antibody being used for a positive reaction.

SLLK, Control Peptide for TSP1 Inhibitor(TFA)

HY-P0301A 5mg
EUR 456

Purified, Bovine S100 protein control for WB

S1001-C 100 ul
EUR 343.2

Positive Control for Anti-Rat MEH Antibody

MEHCON 100 uL
EUR 150

Recombinant (E. coli, >95%) purified human p53 (wild type) protein control for ELISA

P5315-R-10 10 ug
EUR 343.2

Human Pancreatic Amylase protein control for Western blot

PAMY13-C 100 ul
EUR 343.2

ODN 2006-Type B (human, Negative Control)

VAdv-Ly0070 5 mg
EUR 4332
Description: ODN 2006-Type B, human TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant.

ODN 2216-Type A (human, Negative Control)

VAdv-Ly0075-1mg 1 mg
EUR 1528.8
Description: ODN 2216-Type A, human TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant.

ODN 2216-Type A (human, Negative Control)

VAdv-Ly0075-5mg 5 mg
EUR 4332
Description: ODN 2216-Type A, human TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant.

ODN 2336-Type A (human, Negative Control)

VAdv-Ly0077-1mg 1 mg
EUR 1528.8
Description: ODN 2336-Type A, human TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant.

ODN 2336-Type A (human, Negative Control)

VAdv-Ly0077-5mg 5 mg
EUR 4332
Description: ODN 2336-Type A, human TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant.

Human Apolipoprotein B protein control for WB

APOB21-C 100 ul
EUR 343.2

Positive Control for Anti-Rat CYP2C Antibody

P2CCON 100 uL
EUR 150

Positive Control for Anti-Rat CYP2D Antibody

P2DCON 100 uL
EUR 150

Positive Control for Anti-Rat CYP2B1 Antibody

P2B1PTCON 100 uL
EUR 150

Positive Control for Anti-Rat CYP3A2 Antibody

P3A2PTCON 100 uL
EUR 150

Haptoglobin Human Plasma protein control for WB

HGLB18-C 100 ul
EUR 343.2

Control/Blocking peptide for Mouse Vimentin (Vim)

VIM11-C 100 ug
EUR 196.8

ODN 1668-Type B (murine, Negative Control)

VAdv-Ly0071-1mg 1 mg
EUR 1528.8
Description: ODN 1668-Type B, murine TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant.

ODN 1668-Type B (murine, Negative Control)

VAdv-Ly0071-5mg 5 mg
EUR 4332
Description: ODN 1668-Type B, murine TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant.

ODN 2088-Type A (murine, Negative Control)

VAdv-Ly0072-1mg 1 mg
EUR 1528.8
Description: ODN 2088-Type A, murine TLR9 agonist, oligodeoxy nucleotide vaccine adjuvant.


Despite decades of intensive research, many questions remain on the formation and growth of the first cell on earth. Here, we use computer simulations to compare the process of self-assembly of ribonucleic acid in two environments: sealed in the cell membrane vesicles and in such large numbers. self-assembly was found to be preferred in the former environment, and the origin of such biointerface effects identified. These results will contribute to a better understanding of the origins of life on the primitive Earth.

Kathleen

Related Posts

Hypoxia-inducible factors as essential regulators of inflammation.

Hypoxia-inducible factors as essential regulators of inflammation.

Pharmacokinetic clinical and pharmacodynamic micoFenolation at recipients of solid organ transplants.

Pharmacokinetic clinical and pharmacodynamic micoFenolation at recipients of solid organ transplants.

HIF-1 modulates dietary restriction-mediated lifespan extension via IRE-1 in Caenorhabditis elegans.

HIF-1 modulates dietary restriction-mediated lifespan extension via IRE-1 in Caenorhabditis elegans.

Expression of Staphylococcus aureus clumping factor A in Lactococcus lactis subsp. cremoris using a new shuttle vector.

Expression of Staphylococcus aureus clumping factor A in Lactococcus lactis subsp. cremoris using a new shuttle vector.

No Comment

Leave a Reply

Your email address will not be published.

Recent Posts

Tags

December 2023
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031

Categories